Bicara Therapeutics to Present at 34th Annual Piper Sandler Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present a corporate overview at the upcoming 34th Annual Piper Sandler Healthcare Conference, in New York, NY on Thursday, December 1, 2022 at 10:10 a.m. ET.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. Bicara’s lead asset, BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, is currently enrolling patients in a Phase 1/1b study. Bicara’s experienced team brings deep expertise across immunology, oncology, clinical development, business development and operational strategy. More information is available at www.bicara.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005116/en/
Investors
Sarah McCabe
Stern Investor Relations, Inc.
[email protected]
212-362-1200
Media
Chris Railey
Ten Bridge Communications
[email protected]
617-834-0936
Source: Bicara Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sterling Bancorp Reports First Quarter 2024 Financial Results
- Amesite Launches Revolutionary NurseMagic™ App in Beta to Empower 5.2 Million Nurses with AI Tools
- Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!